Warsaw, IN . . . September 25, 2000 . . . (NASDAQ: BMET)

BIOMET ANNOUNCES ACQUISITION OF BIOLECTRON

Biomet, Inc. announced today that its EBI subsidiary has entered into a
definitive agreement to acquire Biolectron, Inc. for $90 million in cash.  The
transaction is expected to close by the end of business today.  Founded in 1977,
Biolectron is a private company with annualized sales of approximately $45
million and recorded $26 million in sales during calendar year 1999.
Biolectron's products principally address the spinal fusion, fracture healing
and arthroscopy market segments.  Dane A. Miller, Ph.D., President and Chief
Executive Officer of Biomet said, "We are excited about the acquisition of
Biolectron.  Biolectron competes effectively in high-growth market segments
where Biomet has an interest in expanding its product portfolio. We believe that
this acquisition will be accretive to Biomet's earnings during fiscal year 2001
and beyond."

Biolectron's non-invasive spinal stimulator, SpinalPak, was approved through a
PMA supplement in September 1999 as an adjunct to spinal fusion surgery for one
or two levels.  SpinalPak's superior clinical success rates further complement
EBI's implantable spinal fusion stimulation product, the SpF system, which has
the highest spinal fusion success rates in the industry. Biomet's EBI subsidiary
will now be able to offer its customers spinal fusion stimulation technology for
use in either inpatient or outpatient settings.    Biolectron's OrthoPak, which
was approved by the FDA in 1986, is a small and lightweight bone growth
stimulation product approved for use in connection with treating non-union
fractures. Combining Biolectron's sales force with EBI's will enable EBI's
expanded sales team to provide greater services and product offerings to its
customers.  Biolectron also manufactures and markets CurvTek, a proprietary
instrument for use in the re-attachment of soft tissue to bone, which will be
merged into Arthrotek, Biomet's arthroscopy subsidiary.  Biolectron's CurvTek
product received clearance from the FDA in October 1997 and will augment
Arthrotek's arthroscopic product portfolio.

Biomet will account for this acquisition as a purchase and will record
approximately $83 million of intangibles, which includes all acquisition
expenditures and closing costs.  Management has not completed its final analysis
of the allocation of the purchase price, but anticipates that the average life
expectancy of these intangibles will be approximately 18 years.

Biomet, Inc. and its subsidiaries design, manufacture and market products used
primarily by musculoskeletal medical specialists in both surgical and
non-surgical therapy, including reconstructive and fixation devices, electrical
bone growth stimulators, orthopedic support devices, operating room supplies,
general surgical instruments, arthroscopy products, spinal implants, bone
cements, bone substitute materials, craniomaxillofacial implants and dental
reconstructive implants and associated instrumentation.  Headquartered in
Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in
more than 100 countries.

For Further information contact Greg W. Sasso, Vice President, Corporate
Development and Communications at (219) 372-1528 or Barbara Goslee, Manager,
Corporate Communications at (219) 372-1514.

All of Biomet's financial information may be obtained on our website at
www.biomet.com or you may contact us by e-mail at
investor.relations@biometmail.com.